These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

330 related articles for article (PubMed ID: 25027709)

  • 1. What parameters from 18F-FDG PET/CT are useful in evaluation of adrenal lesions?
    Kunikowska J; Matyskiel R; Toutounchi S; Grabowska-Derlatka L; Koperski L; Królicki L
    Eur J Nucl Med Mol Imaging; 2014 Dec; 41(12):2273-80. PubMed ID: 25027709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adrenal masses: the value of additional fluorodeoxyglucose-positron emission tomography/computed tomography (FDG-PET/CT) in differentiating between benign and malignant lesions.
    Okada M; Shimono T; Komeya Y; Ando R; Kagawa Y; Katsube T; Kuwabara M; Yagyu Y; Kumano S; Imaoka I; Tsuchiya N; Ashikaga R; Hosono M; Murakami T
    Ann Nucl Med; 2009 Jun; 23(4):349-54. PubMed ID: 19340526
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic importance of 18F-FDG PET/CT parameters and total lesion glycolysis in differentiating between benign and malignant adrenal lesions.
    Ciftci E; Turgut B; Cakmakcilar A; Erturk SA
    Nucl Med Commun; 2017 Sep; 38(9):788-794. PubMed ID: 28692494
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of fluorodeoxyglucose-positron emission tomography/computed tomography in differentiating between benign and malignant adrenal lesions.
    Ozcan Kara P; Kara T; Kara Gedik G; Kara F; Sahin O; Ceylan Gunay E; Sari O
    Nucl Med Commun; 2011 Feb; 32(2):106-12. PubMed ID: 21085046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FDG-PET/CT and FLT-PET/CT for differentiating between lipid-poor benign and malignant adrenal tumours.
    Nakajo M; Jinguji M; Fukukura Y; Kajiya Y; Tani A; Nakajo M; Nakabeppu Y; Arimura H; Nishio Y; Nakamura F; Yoshiura T
    Eur Radiol; 2015 Dec; 25(12):3696-705. PubMed ID: 25925356
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnostic performance of
    Altinmakas E; Hobbs BP; Ye H; Grubbs EG; Perrier ND; Prieto VG; Lee JE; Ng CS
    Abdom Radiol (NY); 2017 Feb; 42(2):577-584. PubMed ID: 27665482
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative characterization of indeterminate large adrenal masses with dual tracer PET-CT using fluorine-18 fluorodeoxyglucose and gallium-68-DOTANOC: initial results.
    Naswa N; Sharma P; Soundararajan R; Patnecha M; Lata S; Kumar R; Malhotra A; Bal C
    Diagn Interv Radiol; 2013; 19(4):294-8. PubMed ID: 23439252
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Use of 18F-FDG-positron emission tomography in presurgical evaluation of nonspecific or suspectious adrenal masses in non-oncologic patients].
    Pavón-Paz I; Rosado-Sierra JA; Balsa-Bretón MÁ; Guijarro-Armas G; Merino-Viveros M; Penín-Gonzalez FJ
    Med Clin (Barc); 2016 Feb; 146(3):104-7. PubMed ID: 26343158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk stratification of adrenal masses by [
    Salgues B; Guerin C; Amodru V; Pattou F; Brunaud L; Lifante JC; Mirallié E; Sahakian N; Castinetti F; Loundou A; Baumstarck K; Sebag F; Taïeb D
    Clin Endocrinol (Oxf); 2021 Feb; 94(2):133-140. PubMed ID: 32978795
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in the characterization of pancreatic masses: experience from tropics.
    Santhosh S; Mittal BR; Bhasin D; Srinivasan R; Rana S; Das A; Nada R; Bhattacharya A; Gupta R; Kapoor R
    J Gastroenterol Hepatol; 2013 Feb; 28(2):255-61. PubMed ID: 23278193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current generation time-of-flight (18)F-FDG PET/CT provides higher SUVs for normal adrenal glands, while maintaining an accurate characterization of benign and malignant glands.
    Koopman D; van Dalen JA; Stigt JA; Slump CH; Knollema S; Jager PL
    Ann Nucl Med; 2016 Feb; 30(2):145-52. PubMed ID: 26644009
    [TBL] [Abstract][Full Text] [Related]  

  • 13.
    Qin C; Shao F; Hu F; Song W; Song Y; Guo J; Lan X
    Eur J Nucl Med Mol Imaging; 2020 May; 47(5):1083-1093. PubMed ID: 31807883
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diagnostic performances of FDG-PET/CT and diffusion-weighted imaging indices for differentiating benign pheochromocytoma from other benign adrenal tumors.
    Nakajo M; Nakajo M; Fukukura Y; Jinguji M; Shindo T; Nakabeppu Y; Kamimura K; Yoneyama T; Takumi K; Yoshiura T
    Abdom Imaging; 2015 Aug; 40(6):1655-65. PubMed ID: 25382022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off.
    Salamon J; Veldhoen S; Apostolova I; Bannas P; Yamamura J; Herrmann J; Friedrich RE; Adam G; Mautner VF; Derlin T
    Eur Radiol; 2014 Feb; 24(2):405-12. PubMed ID: 24097302
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-FDG PET/CT in the evaluation of adrenal masses.
    Metser U; Miller E; Lerman H; Lievshitz G; Avital S; Even-Sapir E
    J Nucl Med; 2006 Jan; 47(1):32-7. PubMed ID: 16391184
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Analysis of adrenal masses by 18F-FDG positron emission tomography scanning.
    Han SJ; Kim TS; Jeon SW; Jeong SJ; Yun M; Rhee Y; Kang ES; Cha BS; Lee EJ; Lee HC; Lim SK
    Int J Clin Pract; 2007 May; 61(5):802-9. PubMed ID: 17343665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance of 18F-FDG PET/CT in the Characterization of Adrenal Masses in Noncancer Patients: A Prospective Study.
    Guerin C; Pattou F; Brunaud L; Lifante JC; Mirallié E; Haissaguerre M; Huglo D; Olivier P; Houzard C; Ansquer C; Hindié E; Loundou A; Archange C; Tabarin A; Sebag F; Baumstarck K; Taïeb D
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2465-2472. PubMed ID: 28431167
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hyperaccumulation of (18)F-FDG in order to differentiate solid pseudopapillary tumors from adenocarcinomas and from neuroendocrine pancreatic tumors and review of the literature.
    Guan ZW; Xu BX; Wang RM; Sun L; Tian JH
    Hell J Nucl Med; 2013; 16(2):97-102. PubMed ID: 23687644
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of dual-time-point (18)F-fluorodeoxyglucose integrated positron emission and computed tomography in differentiation of malignant from benign gastrointestinal diseases].
    Xu XX; Cheng J; Xu WG; Dai D; Song XY; Ma WC; Zhu L; Zhu X
    Zhonghua Zhong Liu Za Zhi; 2012 May; 34(5):364-8. PubMed ID: 22883458
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.